Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: ROY, along with its subsidiaries together referred to as "Dr. Reddy's") today announced that it has launched Colesevelam HCI Tablets, USP, a therapeutic equivalent generic version of WELCHOL (colesevelam HCI) Tablets in the United States market approved by the U.S. Food and Drug Administration (USFDA).
The WELCHOL brand and generic had U.S. sales of approximately $471 million MAT for the most recent twelve months ending in August 2018 according to IMS Health*.
Dr. Reddy's Colesevelam Hydrochloride Tablets is available in 625 mg with 180 count bottle size.
WELCHOL is a registered trademark of Daiichi Sankyo, Inc.
Shares of DR.REDDY'S LABORATORIES LTD. was last trading in BSE at Rs.2446.6 as compared to the previous close of Rs. 2339.05. The total number of shares traded during the day was 64770 in over 3153 trades.
The stock hit an intraday high of Rs. 2470 and intraday low of 2346.55. The net turnover during the day was Rs. 156865133.